全球指数

INNOCARE PHARMA LIMITED(09969.HK):STRONG SALES PERFORMANCE IN 3Q24

上海申银万国证券研究所有限公司2024-11-12
  InnoCare Pharma announced 9M24 revenue of Rmb698m (+30% YoY) and net loss of Rmb275m (-48% YoY), with revenue of Rmb278m (+74% YoY) and net losses of Rmb14m (-88% YoY) in 3Q24, in line with our expectation. Sales of key product, orelabrutinib increased 45% YoY to Rmb693m in 9M24 and reached Rmb276m in 3Q24 (+76% YoY). Its R&D expenses reached Rmb615m (+12% YoY) in 9M24, with R&D expenses reaching Rmb194m (+3% YoY, -21% QoQ) in 3Q24. Its selling expenses reached Rmb274m (+2.5% YoY), with selling expenses ratio down 10.5 ppts to 39% in 9M24. In addition, its gross profit margin increased 4.7 ppts to 86.0% in 9M24. As the end of September 2024, the company has cash of c.Rmb7.8bn on hand. Given its continuous investments in R&D, we lower our EPS forecast from -Rmb0.28 to -Rmb0.30 in 24E, from -Rmb0.19 to -Rmb0.21 in 25E and forecast -Rmb0.06 in 26E. Based on the DCF model, we lower our target price from HK$12.0 to HK$10.0. With 34% upside, we maintain our BUY rating.
  Continuous sales ramp-up of Yinuokai (orelabrutinib). In 9M24, sales of orelabrutinib reached Rmb693m (+45% YoY), with sales of Rmb276m (+76% YoY) in 3Q24. Now, orelabrutinib has been approved by the NMPA for the treatment of r/r CLL/SLL, r/r MCL, and r/r MZL. In addition, orelabrutinib has been added into the CSCO Diagnosis and Treatment Guidelines for the treatment of r/r CLL/SLL, r/r MCL, r/r MZL. With the inclusion of orelabrutinib into the NRDL as a type 2 drug, we expect the continuous sales ramp up of orelabrutinib with the rising penetration rate. Given the strong sales performance of orelabrutinib in 3Q24, the company raise the sales target from 35%+ YoY to 45%+ YoY in 24E.
  Exploring opportunities of orelabrutinib in the autoimmune filed. Apart from the approved indications, orelabrutinib is under development for the 1L treatment for hemato-oncology diseases, including 1L CLL/SLL and 1L MCL. In addition, orelabrutinib is under development for autoimmune diseases, which is now under phase III for ITP, phase II for SLE and NMOSD. In addition, as for the global development of orelabrutinib, the company has initiated the global phase III trial for PPMS and planned to initiate phase III trial for SPMS in 1H25E.
  Expecting NMPA’s approval of Minjuvi (tafasitamab, CD19). Tafasitamab (CD19) has been approved for the urgent clinical use in the Hainan Province in 2022. In June 2024, the BLA for tafasitamab’s combo with lenalidomide for r/r DLBCL who are not eligible for Autologous Stem Cell Transplant (ASCT) was accepted by the NMPA, with BLA approval expected in 1H25E.
  Comprehensive pipeline in autoimmune diseases. Besides the pipelines for the liquid cancer, the company is developing pipelines of autoimmune diseases, such as AD, psoriasis and vitiligo, with ICP-332 (TYK2-JH1)’s phase III trial for the treatment of AD initiated and ICP-488 (TYK2-JH2)’s phase II trial for the treatment of psoriasis completed. Meanwhile, the company has obtained the IND approval from the FDA for ICP-332 in 1H24, which is now under patient enrollment.
  Maintain BUY. Given its continuous investments in R&D, we lower our EPS forecast from -Rmb0.28 to -Rmb0.30 in 24E, from -Rmb0.19 to -Rmb0.21 in 25E and forecast -Rmb0.06 in 26E. Based on the DCF model, we lower our target price from HK$12.0 to HK$10.0. With 34% upside, we maintain our BUY rating.
  Risks: lower-than-expected sales of key product; R&D failure of key pipeline.

免责声明:以上内容仅供您参考和学习使用,任何投资建议均不作为您的投资依据;您需自主做出决策,自行承担风险和损失。九方智投提醒您,市场有风险,投资需谨慎。

推荐阅读

暂无数据

公司动态

    暂无数据

盘面综述

    暂无数据

IPO动态

    暂无数据

港股涨幅榜
  • 港股通
  • 红筹股
  • 国企股
  • 科技股
  • 名称/代码
  • 最新价
  • 涨跌幅

暂无数据

扫码关注

九方智投公众号

扫码关注

九方智投公众号